Skip to Content
Merck
  • Polymorphisms of GSTA1 contribute to elevated cancer risk: evidence from 15 studies.

Polymorphisms of GSTA1 contribute to elevated cancer risk: evidence from 15 studies.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology (2015-03-18)
Qiwen Deng, Bangshun He, Yuqin Pan, Huiling Sun, Xian Liu, Jie Chen, Houqun Ying, Kang Lin, Hongxin Peng, Shukui Wang
ABSTRACT

Glutathione S-transferases (GSTs) are involved in the detoxification of carcinogens, and may be linked to carcinogenesis. As a vital component of GSTs, GSTA1 plays an important role in carcinogenesis. However, the studies about the effect of GSTA1 polymorphisms on cancer risk are limited and the conclusions are contradictory. This meta-analysis aimed to evaluate the association between GSTA1 polymorphisms (-567T>G, (69C>T and -52G>A) and cancer risk. A literature search of PubMed and Web of Science databases was conducted from their inception through December 2013. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the association of GSTA1 polymorphisms and cancer risk. A total of 15 studies were enrolled, and the results indicated that GSTA1 BB genotype was associated with elevated cancer risk, especially in colorectal cancer. Further stratifications showed that GSTA1 BB genotype was associated with increased cancer risk in Caucasian populations and in the study with population-based controls. This meta-analysis suggested that GSTA1 BB genotype was a risk factor for colorectal cancer, especially in Caucasian populations.